Clinical Trials

1,400 enrolled

Breast Neoplasms, Breast Neoplasms, Male

NCT02767661 2026-02-27

MECCA

263 enrolled

Breast Neoplasms

NCT05467891 2026-02-27

RaPhLRR

200 enrolled

Locoregional Recurrence

NCT06179303 2026-02-27

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

60 enrolled

Anatomic Stage III Breast Cancer AJCC v8

NCT03179904 2026-02-24

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

17 enrolled 10 charts

Advanced Breast Carcinoma

NCT04059484 2026-02-24

AMEERA-3

Phase 2 Terminated

367 enrolled 30 charts

Breast Cancer Metastatic

NCT06507618 2026-02-24

POWER II

354 enrolled

Breast Neoplasms

NCT06105632 2026-02-13

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

333 enrolled

Breast Neoplasms, Recurrence

NCT01674140 2026-02-10

e3

1,939 enrolled 15 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT00066690 2026-02-06

SOFT

3,066 enrolled 15 charts

Breast Neoplasms

NCT05306340 2026-01-30

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

373 enrolled

Breast Neoplasms

NCT05514054 2026-01-29

EMBER-4

8,000 enrolled

EndocrineGastrointestinalGenitourinaryNET

Breast Neoplasms

NCT07369505 2026-01-27

Sapu003 in Advanced mTOR-sensitive Solid Tumors

Phase 1 Recruiting

27 enrolled

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Tuberous Sclerosis, Neuroendocrine Tumors

NCT02057133 2026-01-26

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

Phase 1 Active not recruiting

198 enrolled

Breast Neoplasms

NCT07019363 2026-01-21

CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)

1,903 enrolled

Breast Neoplasms

NCT06001762 2026-01-16

TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer

90 enrolled

Breast Neoplasms

NCT04584853 2026-01-14

POETIC-A

123 enrolled

Breast Cancer Female

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

24 enrolled

Phase 3 Enrolling by invitation

Breast Neoplasms

NCT05645536 2026-01-12

Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study

250 enrolled

Breast Neoplasms, Neoplasms

NCT05150652 2026-01-07

Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer

8 enrolled

Breast Neoplasms

NCT06630325 2026-01-07

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

GastrointestinalGenitourinaryGynecologic

30 enrolled

Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT06428396 2025-12-26

LITESPARK-029

120 enrolled

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07299890 2025-12-23

An Exploratory Study of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exemestane as Neoadjuvant Therapy for Triple-Positive Breast Cancer

90 enrolled

Breast Neoplasms

NCT02115282 2025-12-18

Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

608 enrolled 18 charts

Breast Neoplasms

NCT06495164 2025-11-25

A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer

Active not recruiting

1 enrolled

Breast Neoplasms

NCT03079011 2025-11-18

PADA-1

1,017 enrolled

Breast Neoplasms

NCT06086340 2025-11-18

Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.

Completed

779 enrolled 9 charts

Breast Neoplasms, Neoplasm Metastasis

NCT06364267 2025-11-18

BabyTears

140 enrolled

Breast Neoplasms

NCT04569747 2025-11-13

ADEPT

375 enrolled

Breast Neoplasms

NCT03280563 2025-11-10

MORPHEUS HR+BC

Phase 1/2 Completed

144 enrolled 25 charts

Breast Neoplasms

NCT07190443 2025-09-29

AURA

290 enrolled

Breast Neoplasms

NCT06680921 2025-09-22

A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)

460 enrolled

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07179939 2025-09-18

Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study

288 enrolled

Phase 1 Not yet recruiting

HER2-positive Breast Cancer

NCT07163481 2025-09-16

SoGreat

12 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT03778931 2025-09-15

EMERALD

478 enrolled 16 charts 1 FDA

Breast Neoplasms

NCT02007512 2025-09-02

Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer

Phase 2 Completed

247 enrolled 27 charts